Wei Sun

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

Karine Briot, Anthony A. Portale, Maria Luisa Brandi et al. · RMD Open · 2021 · 66 citations · Full text

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

Raja Padidela, Michael P. Whyte, Francis H. Glorieux et al. · Calcified Tissue International · 2021 · 47 citations · Full text

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

Peter Kamenický, Karine Briot, Maria Luisa Brandi et al. · RMD Open · 2023 · 33 citations · Full text

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

Maria Luisa Brandi, Suzanne M. Jan de Beur, Karine Briot et al. · Calcified Tissue International · 2022 · 22 citations

Metabolic Syndrome, Rheumatology, X-linked Hypophosphatemia +10